Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2009 Jun;6(6):306-7.
doi: 10.1038/nrclinonc.2009.69.

Genetics: Predictive value of KRAS mutations in chemoresistant CRC

Astrid Lièvre  1 , Pierre Laurent-Puig
Affiliations
Comment

Genetics: Predictive value of KRAS mutations in chemoresistant CRC

Astrid Lièvre et al. Nat Rev Clin Oncol. 2009 Jun.

Abstract

On the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.

PubMed Disclaimer

Comment on

  • K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
    Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. Karapetis CS, et al. N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385. N Engl J Med. 2008. PMID: 18946061 Clinical Trial.

References

    1. Clin Cancer Res. 2008 Aug 1;14(15):4830-5 - PubMed
    1. J Clin Oncol. 2008 Dec 10;26(35):5705-12 - PubMed
    1. N Engl J Med. 2008 Oct 23;359(17):1757-65 - PubMed
    1. J Clin Oncol. 2004 Apr 1;22(7):1201-8 - PubMed
    1. J Clin Oncol. 2008 Apr 1;26(10):1626-34 - PubMed

MeSH terms